What is the difference between adjuvant and neoadjuvant treatment for Glioblastoma

Adjuvant vs. Neoadjuvant Treatment for Glioblastoma

Great question—these terms describe when treatment happens relative to surgery, and this timing matters significantly for glioblastoma care.

Adjuvant Treatment (After Surgery)

Adjuvant means treatment given after surgery to remove the tumor. For glioblastoma, this is the standard approach.

How it works:

• Your neurosurgeon removes as much of the tumor as safely possible
• After you've recovered from surgery, you receive chemotherapy and/or radiation therapy
• The goal is to eliminate any remaining cancer cells that couldn't be surgically removed

For glioblastoma specifically: The standard adjuvant approach typically includes:

• Radiation therapy to the tumor area
• Temozolomide (Temodar), a chemotherapy drug given during and after radiation

According to the clinical trial information in the glioblastoma immunotherapy research, the control group in newer studies receives "adjuvant temozolomide," confirming this remains a standard treatment sequence.

Neoadjuvant Treatment (Before Surgery)

Neoadjuvant means treatment given before surgery. This is less common for glioblastoma but is being explored in some clinical trials.

How it works:

• You receive chemotherapy and/or radiation therapy first
• After treatment, surgery is performed to remove the tumor
• The goal is to shrink the tumor before surgery, potentially making it easier to remove more completely

Why the Difference Matters for Glioblastoma

The adjuvant approach is standard because:

• Glioblastoma grows aggressively and requires prompt surgical removal
• Delaying surgery for pre-operative treatment could allow the tumor to progress
• Fresh tumor tissue obtained during surgery is valuable for research and personalized treatment planning (like the T-cell immunotherapy approaches discussed in recent glioblastoma studies)

The research on personalized T-cell immunotherapy specifically notes that their current study design focuses on "newly diagnosed MGMT-negative patients with minimal residual disease," emphasizing the importance of surgery first, followed by additional treatments.

Questions to Ask Your Oncology Team

1. Why is adjuvant treatment recommended for my specific situation? (Or if neoadjuvant is suggested, why that approach?)
2. What is my MGMT methylation status, and how does that affect the treatment sequence?
3. Will my tumor tissue be used for any biomarker testing or clinical trial eligibility?
4. What is the timeline between surgery and starting adjuvant therapy?
5. Are there any clinical trials I might be eligible for that could affect treatment sequencing?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.